G.Barekat Pharm (XTEH:BRKT1) Debt-to-Revenue : 0.51 (As of Mar. 2017)

View and export this data going back to 2017. Start your Free Trial

What is G.Barekat Pharm Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

G.Barekat Pharm's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2017 was IRR10,315,378 Mil. G.Barekat Pharm's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2017 was IRR255,897 Mil. G.Barekat Pharm's annualized Revenue for the quarter that ended in Mar. 2017 was IRR20,679,266 Mil. G.Barekat Pharm's annualized Debt-to-Revenue for the quarter that ended in Mar. 2017 was 0.51.

G.Barekat Pharm Debt-to-Revenue Historical Data

The historical data trend for G.Barekat Pharm's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G.Barekat Pharm Debt-to-Revenue Chart

G.Barekat Pharm Annual Data

Trend

Mar16

Mar17

Debt-to-Revenue

0.51

G.Barekat Pharm Semi-Annual Data
	Mar16	Mar17
Debt-to-Revenue	-	0.51

Competitive Comparison of G.Barekat Pharm's Debt-to-Revenue

For the Biotechnology subindustry, G.Barekat Pharm's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

G.Barekat Pharm's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, G.Barekat Pharm's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where G.Barekat Pharm's Debt-to-Revenue falls into.

G.Barekat Pharm Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

G.Barekat Pharm's Debt-to-Revenue for the fiscal year that ended in Mar. 2017 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(10315378	+	255897)	/	20679266
	=	0.51

G.Barekat Pharm's annualized Debt-to-Revenue for the quarter that ended in Mar. 2017 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(10315378	+	255897)	/	20679266
	=	0.51

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is one times the quarterly (Mar. 2017) Revenue data.

G.Barekat Pharm Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of G.Barekat Pharm's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

G.Barekat Pharm (XTEH:BRKT1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » G.Barekat Pharm (XTEH:BRKT1) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 11, 5th Alley, Bucharest Avenue, Argentina Square, Tehran, IRN

Website

http://www.bpharmed.com

G.Barekat Pharm focuses on the introduction of new pharmaceutical fields such as biotechnology, drug delivery which includes nanotechnology, slow release drugs, and new technologies for health, development of cellular molecular industries like tuberculosis, gene therapy, immunotherapy, and tissue technology.

G.Barekat Pharm (XTEH:BRKT1) Headlines

No Headlines